Playing the wrong game

Yesterday shares of Dexcom closed at $173.19 giving the company a market cap of almost $16 BILLION. The Libre has become a critical product for Abbott driving their shares higher as well. When it comes to CGM both companies are gobbling up patients by the boatload, both are making major infrastructure investments adding manufacturing and both have newer systems coming to market, the Libre2 for Abbott and G7 for Dexcom.

The harsh reality is when it comes to CGM this market belongs to Dexcom and Abbott and no one else is even within spitting distance. Yet this won’t . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.